Phase II Study of Antineoplastons A10 and AS2-1 Capsules In Patients With Non Small Cell Lung Cancer
- Demonstrate the antitumor activity of antineoplaston A10 and AS2-1 capsules in patients
with non-small cell lung cancer by determining the proportion of patients who
experience an objective tumor response.
- Evaluate the adverse effects of and tolerance to this regimen in these patients.
OUTLINE: This is an open-label study.
Patients receive antineoplaston A10 and AS2-1 capsules orally six to seven times a day.
Treatment continues in the absence of disease progression or unacceptable toxicity.
Tumors are measured every 4 months for 2 years, every 6 months for 2 years, and then
annually for 2 years.
PROJECTED ACCRUAL: Approximately 20-40 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Stanislaw R. Burzynski, MD, PhD
Burzynski Research Institute
United States: Federal Government
|Burzynski Clinic||Houston, Texas 77055-6330|